Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Abstract: To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an imidazo[1,2-a]pyridine derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

Abstract: A compound of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently H; R3 is selected from H, a C1-C7 straight-chain, and a branched or cyclic alkyl; and R4, R5, R6, R7, and R8 are each independently selected from C1-C7 alkyl, halo C1-C7 alkyl and the like. Also provided is a method for preparing the compound, pharmaceutical compositions including the compound or pharmaceutically acceptable salts thereof, and uses of the compound or pharmaceutically acceptable salt thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO.

Abstract: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.

Abstract: Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.

Abstract: The present invention provides dry powder formulations comprising nicotine, methods of using the same, and methods for making the same. The dry powder formulations may further comprise excipients, therapeutic agents, and flavor components. The dry powder formulations may be manufactured by dry processes and wet processes.

Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.

Abstract: Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.

Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:

Abstract: Methods of treating bladder cancer using terconazole are disclosed herein. Terconazole can be administered as part of a comprehensive treatment program, which can also include chemotherapy, immunotherapy, radiation therapy and/or surgical treatment.

Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

Abstract: A composition for human consumption includes a base composition having a pH of about 2 to about 5 and encapsulated caffeine dispersed throughout at least a portion of the base composition. The encapsulated caffeine can be a caffeine complex. The base composition can include a liquid or a food. An oral pouch product includes a porous pouch wrapper, an inner botanical filling material contained within the pouch wrapper, and encapsulated caffeine dispersed throughout at least a portion of the oral pouch product. The encapsulated caffeine is included in the composition and/or the oral pouch product an amount sufficient to release about 50 mg to about 200 mg of caffeine. The composition can provide immediate release of caffeine and/or release of caffeine over an extended period of time.

Abstract: The present invention refers to the use of theobromine or its derivatives as an inhibitor of the crystallization of uric acid to avoid the formation of uric acid crystals in urine and as a consequence renal lithiasis or specifically uric acid renal lithiasis.

Abstract: The present disclosure describes the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogs/derivatives as well as their acceptable salts, for treating neuropathic pain resulting from chemotherapy. Methods, compositions, dose units and dose forms of tetrodotoxin related to the use are described.

Abstract: Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone.

Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

Abstract: A method of reducing a subject's plasma triglyceride level, comprising administering to a subject in need thereof a gamma-secretase inhibitor in an amount effective to reduce the subject's plasma triglyceride level.

Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.

Abstract: An improved lyophilized cyclophosphamide solid composition is described. The lyophilized cyclophosphamide solid composition is thermally stable, contains anhydrous cyclophosphamide and mannitol, and is substantially free of cyclophosphamide monohydrate. A method for preparing the lyophilized cyclophosphamide solid composition is also provided.

Abstract: The present invention relates to methods for the treatment of migraine headache, cluster headache, tension type headache, trigeminal neuralgia (trigeminal headache) and headache disorders. The methods comprise administration of specific cardiac glycosides: Thevetin A and or Thevetin B to a subject in need thereof a pharmaceutically suitable preparation, in the form of nasal spray and or other modes and methods that will ensure adequate intranasal dosage, a pharmaceutically suitable preparation of the said cardiac glycosides that is sufficient to have the most desirable therapeutic effect when used as a prophylaxis, as a treatment and ameliorating agent of migraine headache and others headache disorders.

Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Abstract: Compounds, pharmaceutical compositions, and methods of using such compounds and compositions to treat or prevent Alzheimer's disease and related tauopathies through the inhibition of USP-9X and/or enhancement of SCF(?-TrCP).

Abstract: A gallium silica glass composition is described. The glass can be used in variety of biomedical applications.

Abstract: A facile approach is described to prepare monodisperse Fe3O4 and Co3O4 nanoparticles on chemically reduced graphene oxide (rGO) to form nanocomposites by low temperature solution route and MWI method, respectively. These processes are environmentally friendly and convenient compared with previously reported methods. The synthesized nanocomposites were characterized using x-ray diffraction spectroscopy (XRD), raman spectroscopy, scanning electron microscopy (SEM) measurements and UV/Vis absorption spectroscopy. XRD patterns revealed the high crystalline quality of the nanocomposites. SEM micrographs showed the morphology of the rGO nanosheets decorated by Co3O4 and Fe3O4 nanoparticles. UV/Vis study revealed the formation of Fe3O4/rGO and Co3O4/rGO nanocomposites with characteristics absorption maxima. Finally, preliminary results of using the Fe3O4/rGO and Co3O4/rGO composites for efficient killing of Human hepatocytes cancer (HepG2) cell are reported.

Abstract: The disclosure discloses a kind of new NKT-like cell subpopulation, a therapeutical composition comprising the NKT-like cell subpopulation, and the medical use thereof. The disclosure also provides a preparation method of the NKT-like cell subpopulation. The disclosed NKT-like cell subpopulation has a strong antitumor effect, and can be adoptive transferred into a subject to treat the tumor in the subject after in vitro cultured and amplified.

Abstract: Disclosed are methods for isolating endothelial progenitor cells (EPC). More particularly, the present invention discloses methods for isolating endothelial progenitor cells that exhibit self-renewal and differentiation capacity. The isolated cellular population of the present invention is useful in a wide range of clinical and research setting including inter alia, the in vitro or in vivo generation of endothelial cells and the therapeutic or prophylactic treatment of a range of conditions via the administration of these cells. Also facilitated is the isolation of endothelial progenitor cells for research purposes such as in vitro based screening systems for testing the therapeutic impact and/or toxicity of potential treatment or culture regimes to which these cells may be exposed to. The present invention also discloses methods for isolating mesenchymal stem cells, in particular mesenchymal stem cells of fetal and/or maternal origin.

Abstract: The method for preparing a tissue construct for medical purposes uses endothelial progenitor cells (EPC) which have not been passaged multiple times and have a content of EOEC (early outgrowth endothelial progenitor cells) and LOEC (late outgrowth endothelial progenitor cells). These cells and fibroblasts and/or muscle cells, viz. myoblasts, myofibroblasts, smooth muscle cells or the progenitors thereof, are, in the form of living cells, seeded onto a matrix or introduced into a matrix in order to yield the tissue construct following further treatment steps. The matrix is preferably a protein preparation, more particularly a fibrinogen preparation. Both the cells and the fibrinogen preparation can be obtained from a single blood sample from a patient. Apart from the preparation of bypass materials, prosthetic vascular graft, tissue patches, conduits and the like, the EOEC-containing EPC culture or suspension is suitable as means for cell transplantation.

Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions.

Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.

Abstract: A method of treating arthritis, which comprising administering to a subject in need an effective amount of Streptococcus thermophilus DSM 28121 strain. The method is especially used for relieving joint pain, alleviating joint swelling, relieving tissue inflammation, protecting cartilaginous tissues and increasing the number of chondrocytes in the cartilaginous tissues.

Abstract: The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.

Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.

Abstract: A method for at least one of preventing osteoporosis, treating osteoporosis, delaying bone loss, increasing bone density, and strengthening bones is provided, wherein the method comprises administering to a subject in need an effective amount of Streptococcus thermophilus TCI633 strain and/or its metabolites. The Streptococcus thermophilus TCI633 strain was deposited at German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, DSMZ) under the accession number DSM 28121.

Abstract: Provided is the new strain Lactobacillus pentosus CECT 7504 and compositions and products comprising said strain and uses in the prevention and/or treatment of candidiasis (oral, intestinal and vaginal) and of bacterial vaginosis.

Abstract: Recombinant vectors comprise simian adenovirus A1321 (SAdV-A1321), SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1321, SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.

Abstract: A method is provided for treating a seaweed extract having a target molecule and a pyrogenic agent. The method includes inactivating the pyrogenic agent and/or removing the pyrogenic agent. The method results in a reduction in pyrogenicity of the extract. The method is useful in the preparation of pharmaceutical compositions and biomaterials for which pyrogen removal is critical.

Abstract: Compounds having unique properties are prepared from the herbal compositions described herein and comprise extracts derived from plants and fungi of the genera Panax, Ganoderma, and Saussurea. The compositions are useful in preventing, treating, relieving, and improving the quality-of-life of patients suffering from chronic diseases, such as liver diseases, cancer, cachexia, and immune system disorders.

Abstract: The invention provides extracts and compositions derived from Tripterygium wilfordii for overcoming drug resistance in cancer therapy. This invention relates to organic solvent extracts of T. wilfordii and their use in cancer treatment, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods of treating a cancer are disclosed. The method administers to a patient in need thereof a combination of (a) an organic solvent extract of T. wilfordii and (b) a chemotherapeutic drug. The organic solvent extract of T. wilfordii (a) and chemotherapeutic drug (b) are administered in a combined amount effective to treat the cancer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug (b) alone. Also disclosed are chemotherapeutic compositions comprising a combination of (a) an organic solvent extract of T.

Abstract: The present invention relates to combinations of an agent that stimulates cell proliferation and an anti-inflammatory/analgesic, which are useful in the treatment of peripheral ulcers of various origins, such as radiation dermatitis, diabetic ulcers, ulcers caused by venous stasis of the limbs, bedsores, and the associated skin infections, proctitis, vulvovaginitis and haemorrhoids with vascular lesions. These combinations can be presented as formulations for topical use.

Abstract: The invention is a method of enhancing female libido by administering an effective amount of a fenugreek extract, for example fenugreek seed extract, to a female in need of enhanced libido. The female can be a human female.

Abstract: Provided herein are plant based formulations for the prevention and management of diabetic vascular complication The formulation include hydro-alcoholic extract of Berberis Aristata, Trigonella foenum-graceum and Salacia parviflora in an effective dose. Also provided herein are methods of using such formulations.

Abstract: The invention relates to a feijoa fruit extract. In particular the invention relates to therapeutic uses of a feijoa fruit extract, processes for preparing the extract, and compositions comprising the extract. The feijoa fruit extract of the invention can be used in the treatment and prevention of rheumatoid arthritis and Type-2 diabetes.

Abstract: The present invention relates to a composition containing a paprika extract as an active ingredient, and more particularly to a pharmaceutical composition or health functional food for preventing or treating inflammatory, allergic or asthma disease, which contains a paprika extract. Particularly, paprika is a natural food which is readily available to anyone, and thus does not cause adverse effects even when it is taken for a long period of time.

Abstract: Systems and methods of weight management and compositions or formulations useful therein are disclosed and described.

Abstract: The present invention is directed to a therapeutic method of treatment of diabetes inducing kidney failure, comprising administering a therapeutically effective amount of Chinese herbal medicine to a subject in need. The Chinese herbal medicine is the decocting extract including the mixture of Grifola, Poria, Atractylodes Lancea Rhizoma, Rhizoma Alismatis, Pimenta officinalis seed, Rhizoma Zingiberis, Radix Aconiti Lateralis Praeparata, Phelloendron amurense bark, Radix Angelicae Sinensis, Radix Astragali, Herb Elephantopus, Honeysuckle Stem, Rhizoma Anemarrhenae, radix Rhubarb, Radix Panax notoginseng, and Radix Ginseng.

Abstract: Provided are methods and compositions for maintaining the viability of photoreceptor cells and/or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and/or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder.

Abstract: A microbial infection in an eye of a subject is treated or prevented by topically administering to the eye an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof that includes a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the outermost generation of the dendrimer. Compositions containing the macromolecule or salt are useful in these methods.

Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.

Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells, and combinations of T cell activating agents and/or an immune checkpoint inhibitors with and without peptides and peptidimimetics. The invention compounds and combinations can be used to inhibit cell growth, such as treat a tumor or cancer.

Abstract: The present invention relates to a novel use of the HIV NC protein, and more particularly, it is relates to a pharmaceutical composition for preventing and treating AIDS having a polypeptide comprising HIV NC protein as an active component and the method of inhibiting HIV proliferation by using the polypeptide. The polypeptide comprising HIV NC protein of the present invention, when it is overexpressed, has the effect on inhibiting HIV proliferation. Accordingly, the present invention provides not only the novel means of inhibition of HIV proliferation, but also the novel method for preventing and treating AIDS.